A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
Abstract Tyrosine kinase inhibitors (TKIs) targeting EGFR-mutant lung cancers promote a range of tumor regression responses to yield variable residual disease, a likely incubator for acquired resistance. Herein, rapid transcriptional responses induced by TKIs early in treatment that associate with t...
Guardado en:
Autores principales: | Natalia J. Gurule, Caroline E. McCoach, Trista K. Hinz, Daniel T. Merrick, Adriaan Van Bokhoven, Jihye Kim, Tejas Patil, Jacob Calhoun, Raphael A. Nemenoff, Aik Choon Tan, Robert C. Doebele, Lynn E. Heasley |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d5ae4b79688c4b8094ee97ddf345427d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition
por: Matthew A. Szaniawski, et al.
Publicado: (2018) -
EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
por: Toshinori Ando, et al.
Publicado: (2021) -
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
por: Jeet Gandhi, et al.
Publicado: (2009) -
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Beth O. Van Emburgh, et al.
Publicado: (2016) -
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)